<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The significance of <z:mp ids='MP_0001845'>inflammation</z:mp> in KSHV biology and <z:mp ids='MP_0002006'>tumorigenesis</z:mp> prompted us to examine the role of COX-2 in primary effusion <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (PEL), an aggressive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-linked KSHV-associated non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) using <z:chebi fb="0" ids="44445">nimesulide</z:chebi>, a well-known COX-2 specific <z:chebi fb="1" ids="35475">NSAID</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>We demonstrate that (1) <z:chebi fb="0" ids="44445">nimesulide</z:chebi> is efficacious in inducing proliferation arrest in PEL (KSHV+/EBV-; BCBL-1 and BC-3, KSHV+/EBV+; JSC-1), EBV-infected (KSHV-/EBV+; Raji) and non-infected (KSHV-/EBV-; Akata, Loukes, Ramos, BJAB) high <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> human Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) as well as KSHV-/EBV+ lymphoblastoid (LCL) cell lines; (2) <z:chebi fb="0" ids="44445">nimesulide</z:chebi> is selectively toxic to KSHV infected endothelial cells (TIVE-LTC) compared to TIVE and primary endothelial cells (HMVEC-d); (3) <z:chebi fb="0" ids="44445">nimesulide</z:chebi> reduced KSHV latent gene expression, disrupted p53-LANA-1 protein complexes, and activated the p53/p21 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-suppressor pathway; (4) COX-2 inhibition down-regulated cell survival kinases (p-Akt and p-GSK-3Î²), an angiogenic factor (VEGF-C), PEL defining genes (syndecan-1, aquaporin-3, and <z:chebi fb="0" ids="28940">vitamin-D3</z:chebi> receptor) and cell cycle proteins such as cyclins E/A and cdc25C; (5) <z:chebi fb="0" ids="44445">nimesulide</z:chebi> induced sustained cell <z:hpo ids='HP_0011420'>death</z:hpo> and G1 arrest in BCBL-1 cells; (6) <z:chebi fb="0" ids="44445">nimesulide</z:chebi> substantially reduced the colony forming capacity of BCBL-1 cells </plain></SENT>
<SENT sid="2" pm="."><plain>Overall, our studies provide a comprehensive molecular framework linking COX-2 with PEL pathogenesis and identify the chemotherapeutic potential of <z:chebi fb="0" ids="44445">nimesulide</z:chebi> in treating PEL </plain></SENT>
</text></document>